
Glycotest
Glycotest Inc.: Global provider of non-invasive blood tests for early detection and treatment of liver diseases.
- 30
- Private company
- Merion Station, PA, USUnited States

Glycotest Inc.: Global provider of non-invasive blood tests for early detection and treatment of liver diseases.
glycotest.comCrawled Oct 16, 2026
Glycotest licenses biomarker IP from the Medical University of South Carolina (MUSC) to develop an advanced blood test for liver fibrosis staging. The agreement, executed through MUSC’s Zucker Institute for Innovation Commercialization, enables Glycotest to expand its diagnostic capabilities. The licensed technology supports next-generation testing for improved fibrosis assessment.
Oct 2026BioQuick NewsNews article
EMV Capital deconsolidates Glycotest and ProAxsis from its portfolio following separate fundraising efforts by both companies. The move occurs after the investment group announced plans to restructure its holdings. EMV Capital operates as a deep tech and life sciences investment firm listed on AIM and Euronext Paris.
Jul 2026Proactiveinvestors NANews article
Glycotest raises $1 million to validate and commercialize its assays following the completion of a major clinical study. The funding supports scaling diagnostic solutions likely tied to glycemic monitoring or related metabolic health applications. The company now advances toward broader market adoption based on clinical trial outcomes.
Jan 2024EMV CapitalNews article
Glycotest Inc. secures $10 million in Series A funding from Shanghai Fosun Pharmaceutical Co., Ltd. The investment supports the company’s focus on glycobiology research and development. Glycotest specializes in technologies targeting glycan-related diseases, aiming to advance therapeutic solutions in this niche field.
Oct 2018BioSpaceNews article